Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gilead Sciences (NQ:GILD)

108.91 -1.17 (-1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Amgen (AMGN) Reports Earnings Tomorrow: What To Expect
Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
From Gilead Sciences, Inc.
Via Business Wire
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
Exposures Political Tariff
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
These S&P500 stocks are moving in today's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Incyte (INCY) Q1 Earnings Report Preview: What To Look For
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Regeneron (REGN) Reports Earnings Tomorrow: What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know. 
Via StockStory
Topics World Trade
Exposures Tariff
Dividend Investor in Mid-50s Making $23,800 A Month Shares Portfolio, Says He Started with $3.50/hour — 'Just 35 Years of Investing'
Via Benzinga
Why Gilead Sciences Stock Slipped Today
Via The Motley Fool
Exposures COVID-19
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?
Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations. 
Via Benzinga
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira. 
Via Stocktwits
Topics World Trade
Exposures Tariff
Gilead Sciences Q1 Earnings Surpass Analyst Expectations, But Revenue Falls Short Of Estimates: Retail’s Optimistic
The company is eyeing FDA approval for its drug, lenacapavir, for HIV prevention by mid-June. 
Via Stocktwits
Topics Government Stocks
Exposures COVID-19 Political Product Safety
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alphabet, Intel And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Which S&P500 stocks are moving after the closing bell on Thursday?
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
Gilead (GILD) Q1 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings World Trade
Exposures Financial Product Safety Tariff
Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance
Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report. 
Via Benzinga
Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Gilead Sciences' Bread-And-Butter Drug Missed Sales Views. And It's Not The Only One.
Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off? 
Via Investor's Business Daily
Exposures COVID-19
Gilead Sciences Announces First Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.